Media Center
Please go to the links below for company and product-related news stories and releases. Fact sheets about our products are also available online. For more information, please contact info@vasgene.com.
Press Releases
Veglin Phase I Trial Shows Potential in Fighting Angiogenesis and Tumor Progression -- New Orleans, June 6, 2004 -- VasGene Therapeutics, Inc. announced the presentation of positive findings from its phase I clinical trial of VEGF-AS (Veglin).
BioWorld Today (PDF) -- December 9, 2003 -- VasGene Therapeutics Inc., of Los Angeles, reported clinical data showing that its Veglin product can be administered safely in a number of cancers and HIV related malignancies through eight escalating dose levels.
Findings of Next-Generation VEGF Cancer Agent Presented at ASH -- San Diego, CA, December 8, 2003 -– Norris-USC Team Presents Data at ASH From Phase I Trial In Relapsed and Refractory Malignancies.